Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Implementation Trial of Implementation Toolkits for Diabetes Coaching

NCT07766811
View directory record Official record
Conditions
Implementation Science, Type 1 Diabetes in Adolescence, Implementation Strategies
Interventions
Base Implementation Toolkit (BIT), BIT-Enhanced, BIT-Sustainment
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer

NCT06022887
View directory record Official record
Conditions
Obesity, Colorectal Cancer, Microbial Colonization, Time Restricted Feeding, Stress, Psychological
Interventions
TRE, MBSR
Behavioral
Lead sponsor
Lisa Tussing-Humphreys
Other
Eligibility
18 Years to 39 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 31, 2026, 7:26 AM EDT
Recruiting No phase listed Observational

Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock

NCT07825363
View directory record Official record
Conditions
Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
Interventions
NIRSense Tissue Oximetry Sensor System
Device
Lead sponsor
NIRSense Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional

Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

NCT03106038
View directory record Official record
Conditions
Intraoperative Ureter Injury
Interventions
Nerindocianine for Injection
Drug
Lead sponsor
Li-Cor, Inc.
Industry
Eligibility
19 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

NCT05320393
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
Drug
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 31, 2026, 7:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Not applicable Interventional Results available

Predictors of Response to Insomnia Treatments for Gulf War Veterans

NCT03208049
View directory record Official record
Conditions
Insomnia
Interventions
Behavioral Therapy (BT), Cognitive Therapy (CT)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Palo Alto, California • Washington D.C., District of Columbia • East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 7:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

NCT04340258
View directory record Official record
Conditions
HNSCC
Interventions
Cesium-131, Pembrolizumab
Device · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
19 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer

NCT01746043
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Armodafinil, Placebo, Minocycline, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 31, 2026, 7:26 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy

NCT05860725
View directory record Official record
Conditions
Human Papillomavirus Infection, Vaccination Hesitancy
Interventions
PSA Development, HPV vaccination focused social marketing campaign
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 31, 2026, 7:26 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Letrozole Treatment in Normal and GnRH Deficient Women

NCT00351416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Letrozole, NAL-GLU GnRH antagonist
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 31, 2026, 7:26 AM EDT
Terminated Phase 2 Interventional Results available

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

NCT04189952
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
Interventions
Acalabrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 31, 2026, 7:26 AM EDT
Terminated Phase 2 Interventional Results available

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

NCT03714555
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Safety Laboratories, AE Assessment, Physical Exam, Concomitant Medication Review, Tumor Imaging, nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate, FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate, Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Diagnostic Test · Other · Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 105 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 31, 2026, 7:26 AM EDT
Recruiting Phase 4 Interventional

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

NCT05183126
View directory record Official record
Conditions
Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
Interventions
Paclitaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

NCT02206087
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, Heparin Sodium
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 31, 2026, 7:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Vascular Pathology With 3D, Time-Resolved Phase Contrast Magnetic Resonance Imaging (MRI)

NCT00722904
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 31, 2026, 7:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints

NCT00292552
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Novel endpoint determination
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
2,747 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Rancho Mirage, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 31, 2026, 7:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

NCT03472547
View directory record Official record
Conditions
Healthy
Interventions
diacerein 1% ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 31, 2026, 7:26 AM EDT
Terminated Phase 2 Interventional Results available

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

NCT02227368
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
Ticagrelor, Comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 31, 2026, 7:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

NCT06063850
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
AAV9-hSyn1-miGRIK2
Genetic
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Not applicable Interventional

The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients

NCT01769690
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DBS stimulator setting alteration, virtual reality simulator
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 31, 2026, 7:26 AM EDT
Withdrawn Phase 1 Interventional

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

NCT01741597
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Recurrent Pancreatic Cancer, Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Interventions
dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD
Procedure · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 31, 2026, 7:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Light Timing Study

NCT04753190
View directory record Official record
Conditions
Chronobiology, Light, Sleep, Circadian Rhythm, Adolescence
Interventions
Baseline Sleep Satiation and Phase Stabilization, Gradually Shifted Sleep
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 20 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 7:26 AM EDT